Evaluation of menogaril in patients with metastatic sarcomas and no prior chemotherapy exposure

Jan Craig Buckner, J. H. Edmonson, J. N. Ingle, Daniel J Schaid

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Menogaril, an anthracycline analog of nogalamycin, is reported to have greater cytotoxicity against certain malignant cell lines and less cardiotoxicity in rabbits than doxorubicin. To evaluate the possible therapeutic benefit of this drug, we studied menogaril in 21 patients with metastatic sarcomas who had received no prior chemotherapy. Menogaril was administered intravenously over 1 h every 3-4 weeks at a dose of 200 mg/m2 in 500 ml of 5% dextrose in water. One patient experienced a partial regression of pulmonary metastases from malignant fibrous histicoytoma of bone (response rate of 5% with 95% confidence interval of 0.1-23.8%). Two additional patients experienced minor reductions in tumor size. The remaining 18 patients had no improvement from menogaril. The median time to disease progression was 7 weeks in all patients treated. Toxicity was acceptable, consisting primarily of leukopenia with 12 patients (57%) and 19 patients (90%) developing nadir leukocyte counts < 2000 and 3000/μL, respectively. Cardiac toxicity was not encountered; however, only seven patients received ≥ 3 cycles of menogaril. We conclude that menogaril does not appear to be useful at this dose and schedule in the treatment of metastatic sarcomas despite the use of near maximal doses in patients with no prior chemotherapy exposure.

Original languageEnglish (US)
Pages (from-to)384-386
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume12
Issue number5
StatePublished - 1989

Fingerprint

Menogaril
Sarcoma
Drug Therapy
Nogalamycin
Anthracyclines
Leukopenia
Leukocyte Count
Doxorubicin
Disease Progression
Appointments and Schedules

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{3b910b560d02453d98e4b1d8a58a6f1b,
title = "Evaluation of menogaril in patients with metastatic sarcomas and no prior chemotherapy exposure",
abstract = "Menogaril, an anthracycline analog of nogalamycin, is reported to have greater cytotoxicity against certain malignant cell lines and less cardiotoxicity in rabbits than doxorubicin. To evaluate the possible therapeutic benefit of this drug, we studied menogaril in 21 patients with metastatic sarcomas who had received no prior chemotherapy. Menogaril was administered intravenously over 1 h every 3-4 weeks at a dose of 200 mg/m2 in 500 ml of 5{\%} dextrose in water. One patient experienced a partial regression of pulmonary metastases from malignant fibrous histicoytoma of bone (response rate of 5{\%} with 95{\%} confidence interval of 0.1-23.8{\%}). Two additional patients experienced minor reductions in tumor size. The remaining 18 patients had no improvement from menogaril. The median time to disease progression was 7 weeks in all patients treated. Toxicity was acceptable, consisting primarily of leukopenia with 12 patients (57{\%}) and 19 patients (90{\%}) developing nadir leukocyte counts < 2000 and 3000/μL, respectively. Cardiac toxicity was not encountered; however, only seven patients received ≥ 3 cycles of menogaril. We conclude that menogaril does not appear to be useful at this dose and schedule in the treatment of metastatic sarcomas despite the use of near maximal doses in patients with no prior chemotherapy exposure.",
author = "Buckner, {Jan Craig} and Edmonson, {J. H.} and Ingle, {J. N.} and Schaid, {Daniel J}",
year = "1989",
language = "English (US)",
volume = "12",
pages = "384--386",
journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Evaluation of menogaril in patients with metastatic sarcomas and no prior chemotherapy exposure

AU - Buckner, Jan Craig

AU - Edmonson, J. H.

AU - Ingle, J. N.

AU - Schaid, Daniel J

PY - 1989

Y1 - 1989

N2 - Menogaril, an anthracycline analog of nogalamycin, is reported to have greater cytotoxicity against certain malignant cell lines and less cardiotoxicity in rabbits than doxorubicin. To evaluate the possible therapeutic benefit of this drug, we studied menogaril in 21 patients with metastatic sarcomas who had received no prior chemotherapy. Menogaril was administered intravenously over 1 h every 3-4 weeks at a dose of 200 mg/m2 in 500 ml of 5% dextrose in water. One patient experienced a partial regression of pulmonary metastases from malignant fibrous histicoytoma of bone (response rate of 5% with 95% confidence interval of 0.1-23.8%). Two additional patients experienced minor reductions in tumor size. The remaining 18 patients had no improvement from menogaril. The median time to disease progression was 7 weeks in all patients treated. Toxicity was acceptable, consisting primarily of leukopenia with 12 patients (57%) and 19 patients (90%) developing nadir leukocyte counts < 2000 and 3000/μL, respectively. Cardiac toxicity was not encountered; however, only seven patients received ≥ 3 cycles of menogaril. We conclude that menogaril does not appear to be useful at this dose and schedule in the treatment of metastatic sarcomas despite the use of near maximal doses in patients with no prior chemotherapy exposure.

AB - Menogaril, an anthracycline analog of nogalamycin, is reported to have greater cytotoxicity against certain malignant cell lines and less cardiotoxicity in rabbits than doxorubicin. To evaluate the possible therapeutic benefit of this drug, we studied menogaril in 21 patients with metastatic sarcomas who had received no prior chemotherapy. Menogaril was administered intravenously over 1 h every 3-4 weeks at a dose of 200 mg/m2 in 500 ml of 5% dextrose in water. One patient experienced a partial regression of pulmonary metastases from malignant fibrous histicoytoma of bone (response rate of 5% with 95% confidence interval of 0.1-23.8%). Two additional patients experienced minor reductions in tumor size. The remaining 18 patients had no improvement from menogaril. The median time to disease progression was 7 weeks in all patients treated. Toxicity was acceptable, consisting primarily of leukopenia with 12 patients (57%) and 19 patients (90%) developing nadir leukocyte counts < 2000 and 3000/μL, respectively. Cardiac toxicity was not encountered; however, only seven patients received ≥ 3 cycles of menogaril. We conclude that menogaril does not appear to be useful at this dose and schedule in the treatment of metastatic sarcomas despite the use of near maximal doses in patients with no prior chemotherapy exposure.

UR - http://www.scopus.com/inward/record.url?scp=0024445645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024445645&partnerID=8YFLogxK

M3 - Article

C2 - 2529759

AN - SCOPUS:0024445645

VL - 12

SP - 384

EP - 386

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

SN - 0277-3732

IS - 5

ER -